Vilin Bio Med Receives NCLT Approval To Convene Merger Meetings

NCLT on Sept 10 allowed Vilin Bio Med's merger application for Chemgenix Laboratories (oncology APIs) into itself at 1:1 exchange, ordering shareholder and creditor meetings Oct 15, 2026 with NSE no-objection; merger claimed EPS and EBITDA accretive. Context: first substantive disclosure beyond FY23 record.